-
Tytuł:
-
Evaluation of prognostic factors in patients undergoing first-line chemotherapy for advanced biliary tract cancer: a retrospective analysis from a South American cancer centre.
-
Autorzy:
-
Felismino TC; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.; https://orcid.org/0000-0002-1055-8118.
Oliveira FMA; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
Fogassa CAZ; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
Santerini SN; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
de Jesus VHF; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
Riechelmann RSP; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
Coimbra FJF; Surgical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
Mello CAL; Clinical Oncology Department, AC Camargo Cancer Center, Rua Professor Antonio Prudente 211, São Paulo, 01509-001, Brazil.
-
Źródło:
-
Ecancermedicalscience [Ecancermedicalscience] 2022 Jan 17; Vol. 16, pp. 1345. Date of Electronic Publication: 2022 Jan 17 (Print Publication: 2022).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Bristol, UK : ecancer
Original Publication: Bristol, UK : Cancer Intelligence
-
References:
-
Arch Surg. 2012 Jun;147(6):513-9. (PMID: 22351874)
Am Soc Clin Oncol Educ Book. 2016;35:e194-203. (PMID: 27249723)
Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5. (PMID: 8857851)
J Am Coll Surg. 2007 Feb;204(2):250-60. (PMID: 17254929)
Hepatology. 2001 Jun;33(6):1353-7. (PMID: 11391522)
PLoS One. 2018 Jan 17;13(1):e0190325. (PMID: 29342161)
J Clin Oncol. 2019 Dec 10;37(35):3392-3400. (PMID: 31513484)
Ann Oncol. 2004 Sep;15(9):1339-43. (PMID: 15319238)
Anticancer Res. 2017 Sep;37(9):5193-5197. (PMID: 28870954)
Lancet Oncol. 2020 May;21(5):671-684. (PMID: 32203698)
Eur J Cancer. 2013 Jan;49(2):329-35. (PMID: 22947649)
Cancer Chemother Pharmacol. 2017 Jul;80(1):209-215. (PMID: 28597043)
Lancet Oncol. 2018 Aug;19(8):e376. (PMID: 30102226)
Ann Oncol. 2016 Jan;27(1):134-40. (PMID: 26483051)
N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404)
PLoS Med. 2007 Jul;4(7):e201. (PMID: 17622191)
Cancer Manag Res. 2019 Mar 29;11:2623-2642. (PMID: 31015767)
Ann Oncol. 2019 May 1;30(5):788-795. (PMID: 30785198)
Int J Oncol. 2014 Jan;44(1):319-26. (PMID: 24247204)
Br J Surg. 2018 Feb;105(3):159-167. (PMID: 29091259)
BMC Cancer. 2018 Sep 20;18(1):906. (PMID: 30236083)
Int J Cancer. 2011 Jun 1;128(11):2717-25. (PMID: 20715167)
Clin Exp Hepatol. 2019 May;5(2):93-102. (PMID: 31501784)
PLoS One. 2017 Sep 20;12(9):e0183288. (PMID: 28931010)
Ann Oncol. 2019 Dec 1;30(12):1914-1924. (PMID: 31613312)
-
Contributed Indexing:
-
Keywords: biliary tract neoplasms; chemotherapy; prognosis
-
Entry Date(s):
-
Date Created: 20220304 Latest Revision: 20220502
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8831103
-
DOI:
-
10.3332/ecancer.2022.1345
-
PMID:
-
35242226
-
Introduction: Biliary tract cancers (BTCs) are rare tumours with regional differences. Prognostic factors are poorly understood. Gemcitabine + platinum (GP) is the standard first-line chemotherapy in metastatic patients. We aimed to search for prognostic factors in patients with advanced disease in a cancer centre in South America.
Methods: We conducted a retrospective analysis of patients with advanced BTC treated with chemotherapy. Variables were age (< or ≥70 years), Eastern Cooperative Oncology Group (ECOG) performance status (0/1 versus 2/3), gender, primary site (intrahepatic (IHC), extrahepatic (EHC), gallbladder (GB)), staging (locally advanced versus metastatic), metastatic sites, albumin (>3.5 g/dL versus <3.5 g/dL), biliary obstruction and first-line chemotherapy (GP, 5FU-based or single-agent). Cox regression method was used to explore factors.
Results: From 2010 to 2017, 104 patients were included. Median age was 62 years (32-86) and 22.1% were older than 70 years. Most patients had ECOG performance status 0/1 (63.4%), were female (51.9%) and were metastatic (82.7%). Bone metastases were found in 19.2%. Primary IHC, EHC and GB were 54.8%, 36.5% and 8.7%, respectively. GP was used by 79.8%. Median follow-up was 32.4 months. Median overall survival (mOS) was 11.4 months. In univariate analysis, male ( p = 0.007), albumin < 3.5 g/dL ( p = 0.001), biliary obstruction ( p = 0.006), 5FU-based ( p = 0.006) and single-agent ( p < 0.0001) were associated with worse OS. ECOG performance status 2/3 ( p = 0.058) and bone metastases ( p = 0.051) were marginally related. In multivariate analysis, male ( p = 0.003), bone metastases ( p = 0.023), biliary obstruction ( p = 0.001), 5FU-based ( p = 0.016) and single-agent ( p = 0.023) were independently associated with inferior OS.
Conclusion: In this retrospective study, we observed that male patients, bone metastases, biliary obstruction and regimens other than GP had worse survival. Larger studies should be conducted to confirm our findings.
Competing Interests: The authors declare that they have no conflicts of interest.
(© the authors; licensee ecancermedicalscience.)
